Antitumor killer lymphocytes in the peripheral blood of a patient with transitional cell carcinoma of the bladder

International Journal of Urology

Volumn 5, Issue 3, 1998, Pages 230-236

  Kim, Chol Jang ^a   Yuasa, Takeshi ^a   Kushima, Ryoji ^a   Tomoyoshi, Tadao ^a   Seto, Akira ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Autologous tumor cell; Bladder cancer; Cytotoxic T cell; Natural killer cell; Transitional cell carcinoma

Indexed keywords

CD56 ANTIGEN; CD8 ANTIGEN;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CASE REPORT; CELL LINE; CELL TRANSFORMATION; CHROMIUM 51 RELEASE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN TISSUE; KILLER CELL; LEUKEMIA CELL; MALE; MYELOID LEUKEMIA; NATURAL KILLER CELL; PHENOTYPE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

EID: 0031812925     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.1998.tb00595.x     Document Type: Article

References (21)

1. Mizutani Y, Nio Y, Yoshida O. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells. J Urol 1992;147:505-510.
2. Mizutani Y, Okada Y, Terachi T, Yoshida O. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer. J Urol 1996,155:888-894.
3. Haas GP, Solomon D, Rosenberg SA. Tumor-infiltrating lymphocytes from nonrenal urological malignancy. Cancer Immunol Immunother 1990;30:342-350.
4. Nouri AME, Bergbaum A, Lederer E, Crosby D, Shamsa A, Oliver RTD. Paired tumor infiltrating lymphocyte (TIL) and tumour cell line from bladder cancer: a new approach to study tumor immunology in vitro. Eur J Cancer 1991;27:608-612.
5. Sternberg CN, Yagoda A. M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. J Urol 1988;139: 461-469.
6. Hisazumi H, Kanokogi M, Nakajima K, Kobayashi T, Tsukahara K, Naito K, Kuroda K. Established cell line of urinary bladder carcinoma (KK-47): growth, hetero-transplantation, microscopic structure and chromosome pattern. Jpn J Urol 1979;70:485-494.
7. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Nagata K, Hinuma Y. Type C virus particles in a cord T-cell line derived by co-cultivating normal human cord leukocytes and human leukaemicT cells. Nature 1981;294: 770-771.
8. 51Cr release assay used for the quantitative measurement of cell-mediated cytolysis in vitro. In: Bloom BR, David JR (eds) In vitro methods in cell-mediated and tumor immunity. New York: Academic Press, 1976:423-428.
9. Nashan B, Wonigeit K, Schwinzer R, Schlitt HJ, Kurrle R, Pichlmayr R. Fine specificity of a panel of antibodies against theTCR/CD3 complex.Transplant Proc 1987;19: 4270-4272.
10. Geisler C, Larsen JK, Plesner T. Identification of αβ and γδ T cell receptor-positive cells. Scand J Immunol 1988,28: 741-745.
11. Bourne SP, Patel K, Walsh F, Popham CJ, Coakham HB, Kemshead JT. A monoclonal antibody (ERIC-1), raised against retinoblastoma, that recognizes the neural cell adhesion molecule (NCAM) expressed on brain and tumors arising from the neuroectoderm. J Neurooncol 1991;10:111-119.
12. Beverley PC, Callard RE. Distinctive functional characteristics of human T lymphocytes defined by E rosetting or a monoclonal antiT cell antibody. Eur J Immunol 1981; 11:329-334.
13. Parnes JR. Molecular biology and function of CD4 and CD8. Adv Immunol 1989;44:265-311.
14. Yoshiki T, Ueda M, Hirano A, Okada K, Yoshida O. Single-step purification of prostatic acid phosphatase: immuno-affinity chromatography with a monoclonal antibody. Int J Urol 1995;2:261-266.
15. Barnstable CJ, BodmerWF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler A. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens - new tools for genetics analysis. Cell 1978;14:9-20.
16. Morales A, Eidinger D, Bruce AW. Intracavitary bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol 1976;116:180-183.
17. Hermann GG, Greertsen PF, von der Masse H, Steven K, Andersen C, Hald T, Zeuthen J. Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer: clinical results and immunological effects. Cancer Res 1992;52:726-733.
18. Chosa T, Yamamoto N, Tanaka Y, Koyanagi Y, Hinuma Y. Infectivity dissociated from transforming activity in a human retrovirus, adult T-cell leukemia virus. Jpn J Cancer Res 1982;76:844-847.
19. Seeley JK, Masucci G, Poros A, Klein E, Golub SH. Studies on cytotoxicity generated in human mixed lymphocyte cultures. (II). Anti-K562 effectors are distinct from allospecific CTL and can be generated from NK-depleted T cells. J Immunol 1979;123:1303-1311.
20. Brooks CG. Reversible induction of natural killer cell activity in cloned murine cytotoxic T lymphocytes. Nature 1983;305:155-158.
21. Suciu-Foca N, Rubinstein P, Rohowsky-Kochan C, Cai J, Popovic M, Gallo RC, King DW. Functional modifications of alloreactive T-cell clones infected with HTLV-1. J Immunol 1986;137:1115-1119.